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Summary
Prostate cancer shows evidence of familial aggregation,
particularly at young ages at diagnosis, but the inherited
basis of familial prostate cancer is poorly understood.
Smith et al. recently found evidence of linkage to mark-
ers on 1q, at a locus designated “HPC1,” in 91 families
with multiple cases of early-onset prostate cancer. Using
both parametric and nonparametric methods, we at-
tempted to confirm this finding, in 60 affected related
pairs and in 76 families with three or more cases of
prostate cancer, but we found no significant evidence of
linkage. The estimated proportion of linked families,
under a standard autosomal dominant model, was 4%,
with an upper 95% confidence limit of 31%. We con-
clude that the HPC1 locus is responsible for only a mi-
nority of familial prostate cancer cases and that it is
likely to be most important in families with at least four
cases of the disease.
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Introduction
Prostate cancer is a significant public health problem. In
the United States, it is the most common malignancy
and the second most common cause of cancer-related
deaths; 209,900 cases and 41,480 deaths were estimated
to have occurred in the United States in 1997 (von Es-
chenbach et al. 1997). Approximately 14,000 cases/year
and 8,742 deaths/year are reported in England and
Wales (Office for National Statistics 1991, 1996). Pros-
tate cancer has traditionally been considered a cancer of
elderly men; however, 13% of cases occur in men !65
years of age; this is just over the total number of testic-
ular cancers reported per year.
Epidemiological studies have clearly demonstrated
that prostate cancer has an inherited component. The
first piece of evidence is the presence of familial clus-
tering. The best examples are the large Utah kindreds
(Cannon et al. 1982; Eeles and Cannon-Albright 1996).
Many other groups have reported familial clusters; in-
terestingly, these are, with few exceptions, small clusters
of three or four cases. The second piece of evidence is
the results of epidemiological studies of prostate cancer
risk among relatives of patients. Woolf (1960) first de-
scribed an increased incidence of prostate cancer in the
relatives of patients. He studied the incidence of prostate
cancer among first-degree relatives of 228 individuals
with prostate cancer and among age-matched controls.
Using data from death certificates, he found that, among
first-degree relatives of prostate cancer patients, the rel-
ative risk (RR) of developing the disease was 3. This RR
is similar to those for other common cancers for which
there is a genetic component.
There have been two types of case-control studies; one
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(eight studies) compares the incidence of prostate cancer
among relatives of cases versus controls, and the other
(five studies) compares the percentage of cases versus
controls with positive family histories of prostate cancer
(summarized in Eeles et al. 1997). Among first-degree
relatives of cases, the RRs of developing prostate cancer
are 1.76–11.00, in the first type of case-control study,
and 0.64–7.50, in the second. Only one study (Steele et
al. 1971) reported a lower RR in relatives, but that study
included only 39 cases. Two cohort studies have been
reported; these showed RRs of 2.20 (95% confidence
interval [CI] 2.00–2.40) and 1.70 (95% CI 1.51–1.90)
(Goldgar et al. 1994; Gro¨nberg et al. 1996).
The increase in RR, evident from the case-control
studies, as clustering becomes more dramatic suggests a
genetic effect; RR markedly increases (up to sevenfold)
as the age of the proband decreases (Cannon et al. 1982),
as the closeness and number of affected members in the
family increases (Steinberg et al. 1990), or when both
factors are taken together (Carter et al. 1992). A change,
of this magnitude, in RR as clustering increases cannot
be explained solely by a common environmental effect
in each cluster.
A segregation analysis of nuclear families suggested
that familial prostate cancer is due to a rare, highly pen-
etrant, dominant gene or genes, the first of which has
been named “HPC1” (Carter et al. 1992). The gene
frequency was estimated to be .0033. This gene is
thought to cause 43% of cases that occur by the age of
55 years and 9% of cases that occur by the age of 80
years.
At present, there is considerable debate about the ge-
netic model for prostate cancer predisposition. Narod et
al. (1995) have suggested that, because the risk of pros-
tate cancer is higher among brothers than among fathers
of affected individuals, a recessive-genetic model should
be used. However, this finding could be explained by a
screening effect that leads to a higher rate of diagnosis
among brothers of affected individuals. Other studies
have suggested an X-linked model (Monroe et al. 1995),
but male-to-male transmission, demonstrated in some
Utah clusters, has refuted this suggestion, at least in some
pedigrees (Cannon-Albright and Eeles 1995). The ob-
servation that, in general, prostate cancer clusters are
smaller than those observed for other common cancers
(e.g., breast and colon cancers) could be explained either
by a lower recall of family history among males or by
the model that prostate cancer predisposition is due to
a more common, lower-penetrance gene than that pre-
dicted in the model of Carter et al. (1992). H. Gro¨nberg
(as discussed in Smith et al. 1996) has estimated a lower
penetrance (63%), with a similar gene frequency. Model-
free methods are therefore very important in linkage
analysis in this disease.
The first prostate cancer–susceptibility locus to be
mapped was reported by Smith et al. (1996), who per-
formed a genomic search in 91 families and found link-
age to chromosome 1q24-25, in prostate cancer clusters
of x3 cases/family. Smith et al. (1996) estimated that
34% of familial cases were attributable to this locus.
The maximum multipoint LOD score was 5.43. In an
attempt to confirm this linkage, we performed genetic-
linkage analysis of 136 prostate cancer families, using
microsatellite markers in the chromosomal region 1q24-
25, as suggested by Smith et al. (1996).
Families and Methods
Families
One hundred thirty-six families with multiple family
members affected with prostate cancer were ascertained
by collaborating urologists in the United Kingdom, Que-
bec, and Texas. The majority (95%) of the U.K. families
were ascertained as a result of clinical presentation;
37.5% of U.S. and Canadian families were ascertained
as a result of clinical presentation. The remaining U.S.
and Canadian families were ascertained as a result of
prostate-specific–antigen serum screens. Diagnoses of all
affected individuals typed by the U.K. and U.S. groups
were confirmed by either medical report or death cer-
tificate. All familial cases in the Canadian group were
reported by the patients; 50% of these were also re-
ported by physicians. Characteristics of the families are
summarized in table 1.
Genotyping
All genotyping was performed on DNA extracted
from lymphocytes. All research groups typed markers
that flank the best estimate (Smith et al. 1996) of the
position of HPC1. A total of six markers, spanning
D1S2883,D1S158, andD1S422, were typed. The mark-
ers (with distance [cM] to adjacent marker) were
D1S212 (2 cM), D1S2883 (6.5 cM), D1S158 (3.5 cM),
D1S238 (3 cM), D1S422 (6 cM), and D1S413 (18 cM).
All groups typed D1S422 and D1S413. The Canadian
group also typed D1S2883, and the Texan group also
typed D1S212 and D1S158. The U.K. group typed all
markers except D1S212. Primer sequences and condi-
tions are shown in table 2.
Fifty nanograms of genomic DNA was amplified. In
the United Kingdom, amplification was performed with
fluorescently labeled primers, and PCR products were
submitted to electrophoresis and were sized by an au-
tomatic ABI 377 (PE-ABI), using the programs GENES-
CAN and GENOTYPER to allocate alleles. In Texas and
Quebec, PCR products were submitted to manual elec-
trophoresis, in 6% polyacrylamide denaturing gels, with
end-labeled 32P primers. Three control individuals were
typed by each group, on each gel, as a sizing check.
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Table 1
Characteristics of Prostate Cancer Families
NO. OF PROSTATE CANCER CASES IN FAMILY
2 3 4 5 6 7 Total
Center:
United Kingdom 26 11 7 2 . . . . . . 46
Quebec 31 26 11 7 1 1 77
Texas 3 4 1 2 2 1 13
Total 60 41 19 11 3 2 136
Average no. of affecteds typed 2.00 2.25 2.38 2.45 2.67 3.00
x2 Cases diagnosed at age:
!60 years 1 4 4 1 1 1
!70 years 32 28 17 8 3 2
NOTE.—One hundred twenty-seven families had at least one pair of affected first-degree rel-
atives, seven families had at least one pair of affected second-degree relatives, and two families
had pairs of affected cousins only.
Table 2
Primers Used for 1q Markers Genotyped
Marker Upstream Primer Downstream Primer
Annealing
Temperature
(C)
D1S212 5′ cagcaagactctgcctctac 5′ ccaggctgattttgtgtatg 55
D1S2883 5′ gtgtctgtatgcagtttg 5′ gtgtctcctctcacatatacaaa 50
D1S158 5′ ggaaagactggaccaaagag 5′ gtttctgggccttcttatattgcttc 59
D1S238 5′ tcatgXctagatcctgtgcc 5′ tggaggcagtttagattgtg 58
D1S422 5′ catggggtatagcaacagac 5′ tgatttcctgcaaacatttt 50
D1S413 5′ gccaagcctgagatcaaaat 5′ acttgaacagattgggattg 50
NOTE.—All PCRs were performed with 1.5 mM Mg2. PCR cycle conditions were
as follows: Initial denaturation step for 2 min at 94C, followed by 40 cycles of 1
min at 94C, 1 min at annealing temperature, and 1 min at 72C. The appropriate
annealing temperature was chosen for each primer pair. PCR was concluded by a
final polymerization for 10 min at 72C.
Statistical Methods
Linkage of prostate cancer to chromosome 1q was
first assessed by parametric LOD-score analysis, based
on the prostate cancer–susceptibility model suggested by
Carter et al. (1992). In this model, susceptibility to pros-
tate cancer was assumed to be due to a dominant sus-
ceptibility allele with population frequency .0033, which
confers a prostate cancer risk, by age 70 years, of 85%
among carriers, compared with a risk of 2% among
noncarriers. Multipoint heterogeneity LOD (HLOD)
scores were computed over the 21-cM region suggested
by Smith et al. (1996) and defined by the markers
D1S212–D1S413.
To guard against the possibility that evidence for link-
age might be missed because of misspecification of the
genetic model, we also analyzed the data by the non-
parametric haplotype-sharing method that is imple-
mented in the program GENEHUNTER (Kruglyak et
al. 1996). This analysis is based on computation of hap-
lotype sharing among affected relatives and, thus, is not
model dependent. Results are summarized in terms of a
statistic, Z, which estimates the excess (over that ex-
pected by chance) haplotype sharing, divided by its SD,
under the null hypothesis of no linkage. Statistical sig-
nificance is assessed by relating Z to a standard normal
distribution. To assess the contribution of HPC1 to
brothers with prostate cancer, haplotype sharing among
affected sibling pairs was also assessed, by use of the
program MAPMAKER/SIBS (Kruglyak and Lander
1995), with the “all pairs” option.
Results
The nonparametric analysis by the program GENE-
HUNTER found no significant evidence for linkage to
the 1q region defined by Smith et al. (1996), either for
all families combined ( at D1S422, )Z  0.56 P  .71
or, separately, for families with fewer than four cases
( , ) or with at least four cases (Z  1.09 P  .86 Z 
, ) (tables 3 and 4).0.72 P  .22
Results of the multipoint heterogeneity analysis are
summarized in tables 3 and 4. Our analysis found no
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Table 3
Analysis of All Prostate Cancer Families
Marker and Relative
Position (cM)
Two-Point
LOD Scorea a
Multipoint HLOD
Score
Multipoint NPL
Score P
D1S212:
.00 3.08 .00 .00 1.17 .88
.40 .00 .00 1.16 .88
.80 .00 .00 1.15 .88
1.20 .00 .00 1.14 .87
1.60 .00 .00 1.13 .87
D1S2883:
2.00 11.42 .00 .00 1.13 .87
3.30 .00 .00 1.06 .86
4.60 .00 .00 .99 .84
5.90 .00 .00 .93 .82
7.20 .00 .00 .86 .81
D1S158:
8.50 5.64 .00 .00 .80 .79
9.20 .00 .00 .75 .77
9.90 .00 .00 .70 .76
10.60 .00 .00 .65 .74
11.30 .00 .00 .60 .72
D1S238:
12.00 2.49 .04 .01 .55 .71
12.60 .04 .01 .55 .71
13.20 .04 .01 .55 .71
13.80 .04 .01 .55 .71
14.40 .04 .01 .56 .71
D1S422:
15.00 8.07 .04 .01 .56 .71
16.20 .04 .01 .60 .72
17.40 .04 .01 .64 .74
18.60 .04 .01 .67 .75
19.80 .04 .01 .71 .76
D1S413:
21.00 7.82 .04 .01 .75 .77
a At tight linkage to each marker ( ).v  .00
significant evidence of linkage to 1q. The overall HLOD
score, for all 136 families, was 0.01, with the estimated
proportion of linked families, a, being 4% (95% CI
0%–31%). For families with at least four cases, the
HLOD score was 0.20, with (95% CIa  20%
0%–63%); for families with three or fewer cases, the
HLOD score was 0.00, with (95% CIa  0%
0%–27%) (table 4). Analysis according to age at di-
agnosis indicated that 90 families had at least two family
members diagnosed at age !70 years; the HLOD for
these families was 0.02 ( ), and the HLOD fora  6.5%
the remaining 46 families was 0.00 ( ).a  0%
The affected-sibling-pair MAPMAKER/SIBS analysis
showed that the best estimates of the proportion of sib-
ling pairs that share no (z0), one (z1), or both haplotypes
(z2) at HPC1 were .25, .50, and .25 (i.e., their null ex-
pectations), respectively; the lower 95% confidence limit
for z0 was .20, at D1S422, and .16, over the entire re-
gion. This would imply that the 1q locus is likely to
explain a sibling RR of !1.56, which compares with the
familial RR, based on epidemiological studies, of 2–3.
Discussion
In our collection of 136 prostate cancer families,
we found no evidence of linkage to the disease, using
markers on chromosome 1q24-25 (two-point LOD 
to 11.42, across the region of the maximum2.49
multipoint LOD reported by Smith et al. 1996). Overall,
only 4% of families are estimated to be linked (upper
95% confidence limit of 31%). The discrepancy between
some of our results and those of Smith et al. (1996) could
be explained, in part, by differences in ethnic back-
ground; all of the families in the present study are Cau-
casian, whereas two families reported by Smith et al.
were African American, and these families contributed
a total LOD of 1.4; this locus may therefore be more
important in families of African origin. A recent study
by Cooney et al. (1997) provides evidence for linkage
at DIS466 (between DIS2883 and DIS158) in 20 families
with an average of 4.4 prostate cancer cases per family;
4 of these families were African American. In contrast,
McIndoe et al. (1997) reported negative two-point LOD
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Table 4
Multipoint Analysis by Number of Prostate Cancer Cases per Family
MARKER AND RELATIVE
POSITION (CM)
X3 CASES (101 FAMILIES) x4 CASES (35 FAMILIES)
a HLOD NPL Score P a HLOD NPL Score P
D1S212:
.00 .00 .00 1.36 .91 .00 .00 .01 .49
.40 .00 .00 1.35 .91 .00 .00 .00 .49
.80 .00 .00 1.35 .91 .00 .00 .00 .48
1.20 .00 .00 1.34 .91 .00 .00 .00 .48
1.60 .00 .00 1.33 .91 .00 .00 .01 .48
D1S2883:
2.00 .00 .00 .33 .91 .00 .00 .02 .48
3.30 .00 .00 1.28 .90 .04 .01 .06 .46
4.60 .00 .00 1.22 .89 .05 .01 .10 .44
5.90 .00 .00 1.17 .88 .06 .01 .15 .42
7.20 .00 .00 1.12 .87 .07 .02 .19 .41
D1S158:
8.50 .00 .00 1.08 .86 .08 .02 .24 .39
9.20 .00 .00 1.06 .86 .10 .04 .30 .36
9.90 .00 .00 1.04 .85 .12 .06 .37 .34
10.60 .00 .00 1.02 .85 .15 .09 .44 .32
11.30 .00 .00 1.00 .84 .17 .12 .50 .29
D1S238:
12.00 .00 .00 .98 .84 .19 .15 .57 .27
12.60 .00 .00 1.00 .84 .19 .16 .60 .26
13.20 .00 .00 1.02 .85 .20 .17 .63 .25
13.80 .00 .00 1.04 .85 .20 .18 .66 .24
14.40 .00 .00 1.07 .86 .20 .19 .69 .23
D1S422:
15.00 .00 .00 1.09 .86 .20 .20 .72 .22
16.20 .00 .00 1.06 .86 .20 .18 .60 .26
17.40 .00 .00 1.04 .85 .20 .16 .49 .30
18.60 .00 .00 1.02 .85 .19 .14 .37 .34
19.80 .00 .00 .99 .84 .17 .12 .26 .38
D1S413:
21.00 .00 .00 .97 .83 .16 .10 .15 .42
scores across the 1q24-25 region in a series of 49 fam-
ilies, none of which were African American.
A more important factor that might explain the dis-
crepancy between our results and those of Smith et al.
(1996) is the fact that the families in the present study
included fewer prostate cancer cases; 73% of the families
in our analysis include X3 affecteds, whereas the av-
erage number of affecteds in Smith’s analysis was 4.9
(3–15). When our data were analyzed according to the
number of affecteds in each cluster, a rose to 20% for
clusters of four or more cases and fell to 0 for clusters
of three or fewer cases. This finding is further supported
by the data reported by Cooney et al. (1997): the evi-
dence for linkage to 1q is stronger in families with an
average of 4.4 prostate cancer cases than in those with
an average of 2.4 cases (nonparametric linkage [NPL]
score 1.72, , vs. NPL score 0.809, ,P  .0451 P  .208
respectively). This difference is analogous to that for
BRCA1 and BRCA2 in breast cancer clusters; these
highly penetrant genes account for 80%–90% of larger
clusters (six or more cases), but they account for a much
lower proportion of families with fewer than four cases
(D. Easton, personal communication). However, in con-
trast to BRCA1 and BRCA2, the 1q locus does not ac-
count for such a high proportion of families, even among
those with very large clusters of prostate cancer cases.
Predisposing mutations inHPC1would therefore be pre-
dicted to cause a high risk of the disease and to explain
a proportion of families with numerous cases, whereas
families with fewer cases will more often be explained
by more common, lower-penetrance genes and/or envi-
ronmental effects.
The MAPMAKER/SIBS analysis of our data estimates
the familial RR of prostate cancer due to HPC1 (under
the assumption that HPC1 acts multiplicatively on risk,
with respect to other loci) to be 1.0, with an upper 95%
confidence limit of 1.56. This compares to an RR of x3,
determined by epidemiological studies, for relatives of
individuals diagnosed at !65 years of age. Moreover, the
familial risks that are due to HPC1 are overestimated
by this method, because many of the families in this
study were selected because they had three or more cases
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of the disease. We conclude that HPC1 is likely to ex-
plain only a small fraction of the overall familial aggre-
gation of prostate cancer.
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